What do systematic reviews say?

Immunoglobulin vs no treatment

Immunoglobulin probably leads to lower measles cases ‐ convalescent serum compared with no treatment (moderate certainty).

• Post‐exposure passive immunisation for preventing measles 2014 · Cochrane Headline outcomes only
  RR 0.21 [0.15, 0.29]
  3 studies · 301 participants
  Moderate

Immunoglobulin vs no treatment

Immunoglobulin probably leads to lower measles cases ‐ adult serum compared with no treatment (moderate certainty).

• Post‐exposure passive immunisation for preventing measles 2014 · Cochrane Headline outcomes only
  RR 0.52 [0.45, 0.59]
  2 studies · 586 participants
  Moderate

Immunoglobulin vs no treatment

Immunoglobulin probably leads to lower measles cases ‐ gamma globulin compared with no treatment (moderate certainty).

• Post‐exposure passive immunisation for preventing measles 2014 · Cochrane Headline outcomes only
  RR 0.17 [0.08, 0.36]
  2 studies · 545 participants
  Moderate

Immunoglobulin vs no treatment

Immunoglobulin leads to lower mortality due to measles compared with no treatment (high certainty).

• Post‐exposure passive immunisation for preventing measles 2014 · Cochrane Headline outcomes only
  RR 0.24 [0.13, 0.44]
  3 studies · 893 participants
  High

Immunoglobulin vs no treatment

Immunoglobulin probably leads to lower complications due to measles compared with no treatment (moderate certainty).

• Post‐exposure passive immunisation for preventing measles 2014 · Cochrane Headline outcomes only
  RR 0.18 [0.05, 0.6]
  3 studies · 832 participants
  Moderate

Immunoglobulin vs no treatment

• Post‐exposure passive immunisation for preventing measles 2014 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Immunoglobulin vs placebo

It is very uncertain whether summary of findings table ‐ Immunoglobulins changes mortality (any cause during hospitalisation or compared with placebo (very low certainty).

• Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection 2023 · Cochrane Headline outcomes only
  RR 0.87 [0.14, 5.27]
  4 studies · 309 participants
  Very low

Immunoglobulin vs placebo

• Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection 2023 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 737 participants
  Moderate

Immunoglobulin vs placebo

Summary of findings table ‐ Immunoglobulins showed no clear difference in adverse events of any severity or seriousness compared with placebo (low certainty).

• Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection 2023 · Cochrane Headline outcomes only
  RR 1.18 [0.78, 1.78]
  5 studies · 340 participants
  Low

Immunoglobulin vs placebo

Summary of findings table ‐ Immunoglobulins showed no clear difference in serious adverse events compared with placebo (low certainty).

• Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection 2023 · Cochrane Headline outcomes only
  RR 1.08 [0.65, 1.79]
  4 studies · 238 participants
  Low